# US 2021/0079031 A1 · New antiviral acyclonucleoside analogues

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0079031 A1
- Document ID: US20210079031A1
- Status: Published application
- Kind: A1
- Application number: 17/050,263
- Filed: 2019-04-23
- Published: 2021-03-18
- Earliest claimed: 2018-04-23
- Assignees: Centre National De La Recherche Scientifique; Universite D'Orleans; NéOvirtech SAS
- Applicants: Centre national de la recherche scientifique; Universite D'Orleans; Neovirtech
- Inventors: Luigi AGROFOGLIO; Vincent ROY; Coralie DE SCHUTTER; Maxime BESSIERES; Franck GALLARDO
- Web page: https://patentgrep.com/patent/US20210079031A1

## CPC

- A61P 31/14: for RNA viruses
- C07F 9/6521: Six-membered rings
- A61P 31/12: Antivirals
- A61P 31/20: for DNA viruses
- C07F 9/6512: having the nitrogen atoms in positions 1 and 3
- C07F 9/6515: having three nitrogen atoms as the only ring hetero atoms
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention concerns a compound having the following formula (I): as well as its use as a medicament, especially for its use for treating viral infections.

## Claims

### Claim 1

A compound having the following formula (I):
wherein:
n is 0, 1 or 2;
“a” is a single or a double bond;
X1, X2, and X3 are, independently from each other, CH or N, preferably one of them being N;
R″ is chosen from the group consisting of: H, NH2, and halogen atoms such as Cl;
R is chosen from the group consisting of:
—NRaRb groups, Ra and Rb being independently from each other H, a (C1-C6)alkyl group or a (C3-C6)cycloalkyl group;
halogen atoms; and
(C1-C6)alkoxy groups;
R′ is a group of formula (1)
wherein R1 and R2 are independently from each other chosen from the group consisting of:
OH;
(C1-C6)alkoxy groups;
—O-A1-O-A2 groups; wherein A1 is an alkylene radical comprising from 1 to 6 carbon atoms, and A2 is a (C1-C20)alkyl group;
—O-A3-O—C(═O)-A4, wherein A3 is an alkylene radical comprising from 1 to 6 carbon atoms, and A4 is a (C1-C6)alkyl group;
—O-A5-O—C(═O)—O-A6, wherein A5 is an alkylene radical comprising from 1 to 6 carbon atoms, and A6 is a (C1-C6)alkyl group;
or R′ is a group of formula (2):
wherein:
R4 is a (C6-C10)aryl group;
R5 is a (C1-C6)alkyl group,
R6 is chosen from the group consisting of: (C1-C6)alkyl groups, and (C6-C10)aryl groups,
R3 is chosen from the group consisting of:
H;
(C1-C6)alkyl groups;
-A7-OH, wherein A7 is an alkylene radical comprising from 1 to 6 carbon atoms; and
-A8-O—C(═O)-A9, wherein A8 is an alkylene radical comprising from 1 to 6 carbon atoms, and A9 is a (C1-C6)alkyl group;
as well as its pharmaceutically acceptable salts or its racemates, diastereoisomers or enantiomers,
for use for the treatment of viral infections, in particular infections due to DNA viruses or RNA viruses.

### Claim 2 (depends on 1)

The compound for the use of claim 1, wherein “a” is a double bond.

### Claim 3 (depends on 1, 2)

The compound for the use of claim 2, having one of the following formulae (II) or (II′):
wherein n, R, R1, R2 and R3 are as defined in claim 1,
as well as its pharmaceutically acceptable salts or its racemates, diastereoisomers or enantiomers.

### Claim 4 (depends on 1)

The compound for the use of claim 1, wherein R is NH2.

### Claim 5 (depends on 1)

The compound for the use of claim 1, wherein R3 is H or —CH2OCOCH3.

### Claim 6 (depends on 1)

The compound for the use of claim 1, having one of the following formulae (III) or (III′):
wherein n, R1, and R2 are as defined in claim 1,
as well as its pharmaceutically acceptable salts or its racemates, diastereoisomers or enantiomers.

### Claim 7 (depends on 1)

The compound for the use of claim 1, wherein R1 and R2, identical or different, are chosen from the group consisting of:
—O-A1-O-A2,
O-A3-O—C(═O)-A4, and
—O-A5-O—C(═O)—O-A6 groups,
A1, A2, A3, A4, A5, and A6 being as defined in claim 1.

### Claim 8 (depends on 1)

The compound for the use of claim 1, wherein R1 and R2, identical or different, are chosen from the group consisting of:
—O—(CH2)3—O—(CH2)15—CH3,
—O—CH2—O—C(═O)-tBu, and
—O—CH2—O—C(═O)—O-iPr

### Claim 9 (depends on 1)

The compound for the use of claim 1, having the following formula (IV):
wherein n, R, R3, R4, R5 and R6 are as defined in claim 1,
as well as its pharmaceutically acceptable salts or its racemates, diastereoisomers or enantiomers.

### Claim 10 (depends on 9)

The compound for the use of claim 9, wherein R3 is H or —CH2OCOCH3.

### Claim 11 (depends on 9)

The compound for the use of claim 9, wherein R4 is a phenyl or naphthyl group.

### Claim 12 (depends on 1)

The compound for the use of claim 1, wherein the viral infections are infections due to viruses chosen from the group consisting of: Hepatitis B virus, Varicella-zoster virus, Cytomegalovirus, Adenovirus, Herpes virus, Poxvirus, Feline corona virus, Filovirus, Papovarirus, Parvovirus, Myxoma virus and Hepadnavirus.

### Claim 13

A compound having the following formula (I′):
wherein:
n is 0, 1 or 2;
X1, X2, and X3 are, independently from each other, CH or N, preferably one of them being N;
R″ is chosen from the group consisting of: H, NH2, and halogen atoms such as Cl;
R is chosen from the group consisting of:
NRaRb groups, Ra and Rb being independently from each other H, a (C1-C6)alkyl group or a (C3-C6)cycloalkyl group;
halogen atoms; and
(C1-C6)alkoxy groups;
R′ is a group of formula (1)
wherein R1 and R2 are independently from each other chosen from the group consisting of:
OH;
(C1-C6)alkoxy groups;
—O-A1-O-A2 groups; wherein A1 is an alkylene radical comprising from 1 to 6 carbon atoms, and A2 is a (C1-C20)alkyl group;
—O-A3-O—C(═O)-A4, wherein A3 is an alkylene radical comprising from 1 to 6 carbon atoms, and A4 is a (C1-C6)alkyl group;
—O-A5-O—C(═O)—O-A6, wherein A5 is an alkylene radical comprising from 1 to 6 carbon atoms, and A6 is a (C1-C6)alkyl group;
or R′ is a group of formula (2):
wherein:
R4 is a (C6-C10)aryl group;
R5 is a (C1-C6)alkyl group,
R6 is chosen from the group consisting of: (C1-C6)alkyl groups, and (C6-C10)aryl groups,
R3 is chosen from the group consisting of:
H;
(C1-C6)alkyl groups;
-A7-OH, wherein A7 is an alkylene radical comprising from 1 to 6 carbon atoms; and
-A8-O—C(═O)-A9, wherein A8 is an alkylene radical comprising from 1 to 6 carbon atoms, and A9 is a (C1-C6)alkyl group;
as well as its pharmaceutically acceptable salts or its racemates, diastereoisomers or enantiomers.

### Claim 14 (depends on 13)

The compound of claim 13, having one of the following formulae (II) or (II′):
wherein n, R, R1, R2 and R3 are as defined in claim 13,
as well as its pharmaceutically acceptable salts or its racemates, diastereoisomers or enantiomers.

### Claim 15 (depends on 13)

The compound of claim 13, having one of the following formulae (III) or (III′):
wherein n, R1, and R2 are as defined in claim 13,
as well as its pharmaceutically acceptable salts or its racemates, diastereoisomers or enantiomers.

### Claim 16 (depends on 13)

The compound of claim 13, having the following formula (IV):
wherein n, R, R3, R4, R5 and R6 are as defined in claim 13,
as well as its pharmaceutically acceptable salts or its racemates, diastereoisomers or enantiomers.

### Claim 17 (depends on 13)

A medicament comprising a compound according to claim 13, or a pharmaceutically acceptable salt thereof.

### Claim 18 (depends on 12)

The compound of claim 12, wherein R1 and R2, identical or different, are chosen from the group consisting of:
—O-A3-O—C(═O)-A4, and
—O-A5-O—C(═O)—O-A6 groups,
A1, A2, A3, A4, A5, and A6.

### Claim 19 (depends on 12)

The compound of claim 12, wherein R1 and R2, identical or different, are chosen from the group consisting of:
—O—(CH2)3—O—(CH2)15—CH3,
—O—CH2—O—C(═O)-tBu, and
—O—CH2—O—C(═O)—O-iPr
